Lipocine Inc. Q3 FY26 Results

Summary

Lipocine Inc. announced its financial results for the third quarter ended September 30, 2026, reporting a reduced net loss of $0.7 million compared to $3.2 million in the prior year. Total revenue surged to $2.3 million from $115,000 year-over-year, primarily due to license and collaboration revenue. The company also highlighted significant progress in its product pipeline, including Health Canada's approval of TLANDO® and marketing authorization in the UAE, with planned launches in early 2027. Lipocine's cash position also strengthened, reaching approximately $28.5 million as of early November 2026.

Key Highlights

1. 1

   Lipocine reported a net loss of $0.7 million, or ($0.08) per diluted share, for the quarter ended September 30, 2026, an improvement from a net loss of $3.2 million, or ($0.59) per diluted share, in the prior year quarter.

2. 2

   Total revenue for the third quarter of 2026 was $2.3 million, a significant increase from $115,000 in the third quarter of 2025, driven by license and collaboration revenue.

3. 3

   Revenue for the nine months ended September 30, 2026, was $2.6 million, up from $831,000 in the comparable period of 2025.

4. 4

   As of September 30, 2026, Lipocine had $21.5 million of unrestricted cash, cash equivalents and marketable investment securities, increasing to approximately $28.5 million as of November 4, 2026.

5. 5

   Health Canada approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males in September 2026, with a planned launch in Canada in early 2027.

6. 6

   Lipocine received product marketing authorization approval in the United Arab Emirates for TESTYRA® (TLANDO) in July 2026, with a planned launch in the UAE in early 2027.